Community: Heparin V/S Warfarin
Community: Heparin V/S Warfarin
Community: Heparin V/S Warfarin
Digoxin
Digitalis Glycosides exert positive inotropic effects through improved availability of calcium to myocardial
contractile elements, thereby increasing cardiac output in CHF.
In CHF, digoxin improves the symptoms of CHF but
does not alter long-term mortality. Antiarrhythmic actions of digoxin are caused by an increase in AV nodal
refractory period via vagal tone, sympathetic withdrawal, and direct mechanisms.
Digoxin also exerts a moderate, direct vasoconstrictor action on arterial venous smooth muscle.
Missed Doses: Take this drug at regular intervals. If you miss a dose and is has been less than 12 hours since
your dose was due, take it as soon as you remember. If it is about time for the next dose, take the dose only. Do
not double dose or take extra.
Serum Levels: Therapeutic: 0.5 – 2.0 g/L
Adverse Reactions: Arrhythmic, listed by decreasing prevalence, are premature ventricular beats, second- and
third-degree heart blocks, AV junctional tachycardia, atrial tachycardia with block, ventricular tachycardia, and
SA
nodal block. Visual disturbances are related to serum level and occur in up to 25% of patients with digoxin
intoxication. They include blurred vision, yellow or green tinting, flickering light or halos, or red-green color
blindness. GI symptoms occur frequently and include abdominal discomfort, anorexia, nausea, and vomiting.
CNS
side effects occur frequently but are nonspecific, such as weakness, lethargy, disorientations, agitation, and
nervousness. Hallucinations and psychosis have been reported. Rare reactions include gynecomastia,
hypersensitivity, and thrombocytopenia.
Contraindications: hypertrophic obstructive cardiomyopathy; suspected digitalis intoxication; second- or
third- degree heart block in the absence of mechanical pacing; atrial fibrillation with accessory AV pathway;
ventricular fibrillation.
Drug Interactions: Beta-blockers can worsen CHF or digoxin-induced bradycardia. Potassium loss caused by
amphotericin B or diuretic can contribute to digoxin toxicity. Spironolactone can decrease digoxin renal
elimination.ACE inhibitors, amiodarone, bepridil, diltiazem, nitredipine, quinidine, and verapamin can increase
digoxin levels.Oral antacids, kaolin-pectin, oral neomycin, and sulfasalazine can reduce digoxin absorption.
Paremeters to Monitor: Obtain serum levels only when compliance, effectiveness, or systemic availability is
questioned or toxicity is suspected. Monitor HR, ECG for digoxin-induced arrhythmias, subjective complaints
oftoxicity, and renal function. Monitor serum electrolytes (especially potassium) frequently initially and then q
1-2months when stabilized.
Toxicity: Treatment of severe or life-threatening digoxin toxicity should include IV Digoxin Immune Fab
(Digibind). About 40 mg (one vial) of digoxin-specific Fab fragments binds 0.6 mg of the glycoside. Exact
dosage can be calculated based on estimated total body stores.
Heparin Warfarin
Structure
Large anionic polymer, acidic Small lipid-soluble molecule
Normal Values aPTT: 20-26seconds With heparin PT 9.6 - 11.8 seconds (male adult);
therapy: 1.5 and 2.5 and 9.5 - 11.3 (female adult) With
times normal warfarin therapy: 1.5-2 times
normal
4. THROMBOLYTICS- which acts on dissolving the clots: Streptokinase, Urokinase - Aminocaproic Acid
( Amicar)